title: Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C.
abstract: OBJECTIVE
  Whether new biomarkers contribute significantly to the existing, simple noninvasive test (comprising of routine laboratory parameters such as the AST to platelet ratio index (APRI)) for predicting liver fibrosis remains unknown.
  
  
  METHODS
  We measured 7 biomarkers in 91 patients with chronic hepatitis C (CHC): haptoglobin, apolipoprotein A1, α2-macroglobulin, hyaluronic acid, type III procollagenic peptide, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-1.
  
  
  RESULTS
  The "multibiomarker" score (based on regression coefficients of significant biomarkers) is an independent predictive factor for significant fibrosis [APRI-adjusted odds ratio, 2.41 (95% CI, 1.28 to 4.55)]. However, the incorporation of the multibiomarker score into the APRI resulted in only a small diagnostic improvement [0.83 (95% CI, 0.74 to 0.92) vs. 0.79 (0.69 to 0.89); p=0.19].
  
  
  CONCLUSIONS
  For assessing significant fibrosis in individual CHC patients, the 7 contemporary biomarkers that we studied add only modestly to the readily available, simple noninvasive index.
authors.affiliation: Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
authors.forename: Seung Ha
authors.initials: SH
authors.lastname: Park
authors.forename: Chang Hoon
authors.initials: CH
authors.lastname: Kim
authors.forename: Dong Joon
authors.initials: DJ
authors.lastname: Kim
authors.forename: Ki Tae
authors.initials: KT
authors.lastname: Suk
authors.forename: Jong Ha
authors.initials: JH
authors.lastname: Park
authors.forename: Jae Youn
authors.initials: JY
authors.lastname: Cheong
authors.forename: Sung Won
authors.initials: SW
authors.lastname: Cho
authors.forename: Seong Gyu
authors.initials: SG
authors.lastname: Hwang
authors.forename: Youn Jae
authors.initials: YJ
authors.lastname: Lee
authors.forename: Mong
authors.initials: M
authors.lastname: Cho
authors.forename: Jin Mo
authors.initials: JM
authors.lastname: Yang
authors.forename: Ha Young
authors.initials: HY
authors.lastname: Park
authors.forename: Young Bae
authors.initials: YB
authors.lastname: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016632:Apolipoprotein A-I / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood; D024061:Collagen Type III / Q000097:blood; D005260:Female; D006242:Haptoglobins / Q000378:metabolism; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications*; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood*; D008103:Liver Cirrhosis / Q000097:blood / Q000175:diagnosis* / Q000209:etiology; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood; D008875:Middle Aged; D015999:Multivariate Analysis; D012372:ROC Curve; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood; D055815:Young Adult; D000511:alpha-Macroglobulins / Q000378:metabolism*
chemical_list: D016632:Apolipoprotein A-I; D015415:Biomarkers; D024061:Collagen Type III; D006242:Haptoglobins; D019715:Tissue Inhibitor of Metalloproteinase-1; D000511:alpha-Macroglobulins; D006820:Hyaluronic Acid; D001219:Aspartate Aminotransferases; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2